证券代码：601089 证券简称：福元医药 公告编号：临 2023-029 北京福元医药股份有限公司 关于 2023 年半年度募集资金的存放与实际使用情况 的专项报告 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准北京福元医药股份有限公司首次公 开发行股票的批复》（证监许可[2022]974 号）核准，公司首次向社会公开发行 人民币普通股（A 股）股票共计 12,000 万股，发行价格为每股人民币 14.62 元， 股票发行募集资金总额为人民币 1,754,400,000 元，扣除所有股票发行费用 （ 不 含 增 值 税 ， 包 括 承 销 及 保 荐 费 用 以 及 其 他 发 行 费 用 ） 人 民 币 118,480,188.68 元，实际募集资金净额为人民币 1,635,919,811.32 元。 首次公开发行股票的募集资金于 2022 年 6 月 27 日由中信建投证券股份 有限公司在按规定扣除相关保荐承销费用后划付至公司指定募集资金账户，并 经天健会计师事务所（特殊普通合伙）审验，出具《验资报告》（天健验 [2022]315 号）。 （二）募集资金使 ...

陈劲 李立东 北京福元医药股份有限公司独立董事 关于第二届董事会第六次会议相关事项的独立意见 根据中国证券监督管理委员会《上市公司独立董事规则》《上市 公司治理准则》等法律、法规以及根据《北京福元医药股份有限公司 章程》《北京福元医药股份有限公司独立董事工作制度》等相关规定， 我们作为北京福元医药股份有限公司（以下简称"公司"）的独立董 事，对公司第二届董事会第六次会议相关议案发表如下独立意见： 一、关于2023年半年度募集资金的存放与实际使用情况的独立意 见 经核查，我们认为公司《关于2023年半年度募集资金的存放与实 际使用情况的专项报告》中的募集资金存放和使用相关信息及时、真 实、准确、完整。2023年半年度，公司募集资金的管理和使用符合中 国证券监督管理委员会和上海证券交易所关于上市公司募集资金存 放和使用情况的相关规定，不存在募集资金存放和使用违规的情形。 我们同意本议案。 （以下无正文） （本页无正文，为独立董事关于第二届董事会第六次会议相关事项 的独立意见签署页） 独立董事： 王秀萍 郑晓东 2023 年 08 月 11 日 ____________ ____________ _________ ...

证券代码：601089 证券简称：福元医药 公告编号：临2023-027 北京福元医药股份有限公司 第二届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京福元医药股份有限公司（以下简称"公司"）第二届董事会第六次会议于 2023 年 8 月 1 日以书面及邮件等方式发出会议通知，并于 2023 年 8 月 11 日在北京以现 场结合通讯表决的方式召开会议。会议应参加表决的董事 9 名，实际参加（授权）表 决的董事 9 名，董事石观群先生因公务原因无法出席本次会议，已授权董事胡少羿女 士代为行使表决权。会议由董事长黄河先生主持召开，监事及高级管理人员列席会议。 会议召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于 2023 年半年度报告及摘要的议案》 具体内容详见公司披露于上海证券交易所网站的《2023 年半年度报告》《2023 年半年度报告摘要》。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 （二 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2023-028 北京福元医药股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北京福元医药股份有限公司（以下简称"公司"）第二届监事会第六次会议于 2023 年 8 月 1 日以书面及邮件等方式发出会议通知，并于 2023 年 8 月 11 日在北京以 现场结合通讯表决的方式召开会议。公司应参加表决的监事 3 名，实际参加表决的监 事 3 名，会议由监事会主席赵嘉女士主持召开。会议召开符合法律法规、《公司法》及 《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 表决情况：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 (一)公司 2023 年半年度报告的编制和审议程序规范合法，符合法律、法规、公司 章程和公司内部管理制度的各项规定，内容真实、准确、完整。 (二)公司 2023 年半年度报告的内容和格式符合中国证监会和上海证券交易所的各 项规定，所包含的信息真实客观反映了公司 202 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2023-026 北京福元医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 一、 说明会类型 会议召开时间：2023 年 08 月 17 日(星期四) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 10 日(星期四) 至 08 月 16 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@foyou.com.cn 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 819,176,868.99, representing a year-on-year increase of 9.56%[5] - The net profit attributable to shareholders for the same period was CNY 113,705,518.99, reflecting a growth of 32.85% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 110,453,764.60, which is an increase of 38.66% year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.24, unchanged from the previous year[6] - The company's net profit for Q1 2023 reached CNY 115,180,784.67, a 34.0% increase compared to CNY 85,993,898.93 in Q1 2022[22] - Operating profit for Q1 2023 was CNY 128,371,945.32, representing a 34.5% increase from CNY 95,402,037.07 in Q1 2022[21] - Total revenue from sales and services amounted to CNY 768,393,348.37, an increase from CNY 698,299,027.48 in Q1 2022[26] - The company reported a total comprehensive income of CNY 115,180,784.67, compared to CNY 85,993,898.93 in the previous year[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,389,551,999.81, an increase of 1.57% from the end of the previous year[6] - The company's cash and cash equivalents amounted to RMB 2,234,007,135.50 as of March 31, 2023, compared to RMB 2,541,250,325.65 at the end of the previous period[16] - Total assets increased to RMB 4,389,551,999.81 as of March 31, 2023, from RMB 4,321,559,033.18 in the previous period, marking a growth of 1.57%[17] - Total liabilities decreased to RMB 1,096,041,312.29 from RMB 1,143,012,517.50, indicating a reduction of 4.12%[18] - The company's equity attributable to shareholders rose to RMB 3,287,522,769.50, up from RMB 3,174,033,863.34, reflecting an increase of 3.57%[18] Cash Flow - The net cash flow from operating activities was CNY 82,973,037.29, showing a decrease of 3.42% compared to the same period last year[5] - Cash flow from operating activities generated CNY 82,973,037.29, slightly down from CNY 85,907,088.90 in the same period last year[26] - The cash and cash equivalents at the end of Q1 2023 were CNY 2,233,696,135.50, down from CNY 2,540,939,325.65 at the beginning of the quarter[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,242[12] - The top shareholder, Xinheng Holdings Group Co., Ltd., held 176,316,354 shares, accounting for 36.7% of the total shares[12] Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 697,038,640.20, up from RMB 654,296,998.45 in Q1 2022, reflecting a year-over-year increase of 6.55%[20] - The company’s total operating expenses increased to CNY 726,393,620.19, up from CNY 626,208,958.59 in the previous year[26] - Research and development expenses increased to CNY 70,612,425.92, up 42.3% from CNY 49,602,481.80 in the previous year[21] - The company incurred financial expenses of CNY -13,068,037.21, compared to CNY -382,589.45 in Q1 2022[21] Market Strategy - The company is focusing on expanding its market presence and enhancing product development strategies in the upcoming quarters[20] Miscellaneous - The weighted average return on equity decreased by 3.30 percentage points to 3.52%[6] - Inventory levels were reported at RMB 340,817,417.24, slightly up from RMB 339,097,725.33, indicating a marginal increase of 0.51%[16] - There are no significant changes in the shareholder structure or related party transactions reported during this period[16] - The company reported non-recurring gains of CNY 3,251,754.39 for the quarter[9] - The company reported a net profit margin improvement, with net profit figures to be detailed in the full report[20]

北京福元医药股份有限公司 关于召开2023年一季报业绩说明会的公告 证券代码：601089 证券简称：福元医药 公告编号：临2023-019 会议召开时间：2023 年 05 月 05 日（星期五）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集： 投 资 者 可 于 2023 年 05 月 05 日 前 访 问 网 址 https://eseb.cn/145pSmSnM1q 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 举办北京福元医药股份有限公司 2023 年一季报业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 二、说明会召开的时间、地点和方式 会议召开时间：2023 年 05 月 05 日（星期五）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 三、参加人员 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完 ...

Financial Performance - The total revenue for 2022 was CNY 3,240,160,465.12, representing a 14.18% increase compared to CNY 2,837,716,899.79 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 438,463,234.35, which is a 39.43% increase from CNY 314,473,914.94 in 2021[25]. - The proposed cash dividend for 2022 is CNY 4 per 10 shares, totaling CNY 192,000,000, resulting in a cash dividend payout ratio of 43.79%[5]. - The net profit attributable to shareholders for the year 2022 was CNY 413,494,591.21, representing a 37.07% increase compared to the previous year[26]. - The total assets at the end of 2022 reached CNY 4,321,559,033.18, an increase of 100.71% from the previous year[29]. - Basic earnings per share for 2022 were CNY 1.04, up 19.54% from CNY 0.87 in 2021[30]. - The weighted average return on equity decreased to 20.25% in 2022, down 8.59 percentage points from 28.84% in 2021[30]. - The operating cash flow for the fourth quarter of 2022 was CNY 246,166,080.69, showing a significant increase compared to previous quarters[32]. - The company reported a net cash flow from operating activities of CNY 659,764,826.04 for the year 2022, reflecting a strong operational performance[26]. - The total equity attributable to shareholders increased significantly due to public stock issuance, contributing to the overall growth in net assets[30]. Research and Development - The company invested 23,974.07 million yuan in R&D, representing a year-on-year increase of 33.44%[40]. - The company has established four major technology platforms to support its R&D efforts[49]. - The company has 51 projects in generic drug development and 5 in innovative drug development[50]. - The company is focusing on R&D in major diseases and chronic conditions, employing a dual strategy of high-end generics and innovative drugs[90]. - The company has multiple ongoing R&D projects, including a GLP-1 drug for diabetes and obesity, currently in the drug discovery phase[91]. - The company's R&D investment accounted for 7.40% of its operating revenue, with a total R&D expenditure of 63,425.95 million RMB, which is higher than the industry average of 53,918.03 million RMB[95]. - The company has a capitalized R&D expenditure ratio of 0%, indicating that all R&D expenses were expensed in the current period[95]. Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the coming years[30]. - The company plans to expand its market presence through new product launches and strategic partnerships[90]. - The company is actively pursuing mergers and acquisitions to bolster its market position and diversify its product offerings[126]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[121]. - The company is adapting to the dynamic adjustment mechanisms of medical insurance payments, which are becoming more standardized and refined[80]. Environmental Responsibility - The company is committed to safety and environmental protection in production, implementing an information platform for safety production[40]. - The company has established a comprehensive environmental management system to ensure compliance with pollution discharge standards, with all pollutants below regulatory limits[196]. - The company has implemented strategies to manage hazardous waste effectively, with all hazardous waste disposed of by qualified units[173]. - The company has a continuous monitoring system for wastewater and waste gas emissions, ensuring real-time compliance with environmental standards[195]. - The company has actively engaged in ecological protection and green development initiatives, reinforcing its commitment to environmental responsibility[197]. Governance and Compliance - The company is committed to ensuring the authenticity, accuracy, and completeness of the financial report[4]. - The audit report issued by Tianjian Accounting Firm is a standard unqualified opinion[5]. - The governance structure has been enhanced to ensure compliance with laws and regulations, safeguarding the rights of shareholders and creditors[117]. - The company has established a comprehensive internal control system to ensure compliance with legal regulations and protect shareholder rights[163]. - The company has maintained its commitment to transparency in executive compensation, adhering to its internal regulations[134]. Employee Management - The total number of employees in the parent company is 1,680, while the main subsidiaries have 1,576 employees, totaling 3,256 employees[150]. - The company has established a standardized salary management system to enhance the rationality, fairness, and incentive of employee compensation[153]. - The company’s employee compensation includes fixed salary, variable salary, and welfare allowances[153]. - The management team includes experienced professionals with backgrounds in various sectors, ensuring strategic oversight and operational efficiency[127]. Risks and Challenges - The company faces risks related to drug and medical device R&D, including high capital investment, technical challenges, and regulatory changes that could delay product launches[112]. - The ongoing national drug procurement policy may lead to risks of not winning bids or further price reductions, potentially slowing down business performance[112]. - The pharmaceutical industry is experiencing intensified competition in the generic drug sector, with a focus on original drug replacements and increased market concentration[80].

证券代码：601089 证券简称：福元医药 公告编号：临 2023-017 北京福元医药股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事长及总经理：黄河先生 http://roadshow.sseinfo.com/） 北京福元医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 04 月 25 日 上午 10:00-11:00 举行 2022 年度业绩说明会，就投资者关心的 问题进行交流。 一、 说明会类型 会议召开时间：2023 年 04 月 25 日(星期二) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二) 至 04 月 24 日(星期 一)16:00 前登录上证路演中心网站首页点 ...

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥822.43 million, representing a 14.06% increase compared to ¥721.06 million in the same period last year[10]. - Net profit attributable to shareholders was approximately ¥125.02 million, a 28.02% increase from ¥97.62 million in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥113.01 million, reflecting a 19.15% increase from ¥94.80 million year-on-year[10]. - Total operating revenue for the first three quarters of 2022 reached ¥2,365,674,217.96, an increase of 15.7% compared to ¥2,043,484,650.29 in the same period of 2021[34]. - Net profit for Q3 2022 was ¥333,009,164.40, representing a 27% increase from ¥262,492,112.90 in Q3 2021[37]. - Earnings per share for Q3 2022 was ¥0.83, compared to ¥0.72 in Q3 2021, reflecting a 15.3% increase[37]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.09 billion, an increase of 90.04% compared to the previous year's end[10]. - Shareholders' equity attributable to the parent company was approximately ¥3.07 billion, a significant increase of 153.33% from ¥1.21 billion year-on-year[10]. - Total current assets as of September 30, 2022, reached RMB 3,159,617,178.11, a significant increase from RMB 1,279,419,125.39 in the previous year[24]. - Total liabilities included accounts payable of RMB 114,057,259.70, down from RMB 129,768,747.00, indicating a decrease of about 12%[27]. - The total liabilities increased to ¥1,017,228,732.47, compared to ¥937,856,701.97 in the previous year, marking an 8.5% rise[34]. Cash Flow - The company reported a net cash flow from operating activities of approximately ¥413.60 million for the year-to-date period, up 5.04% from ¥393.76 million in the previous year[10]. - The net cash flow from operating activities for the first three quarters of 2022 was CNY 413,598,745.35, an increase from CNY 393,758,907.86 in the same period of 2021, representing a growth of approximately 3.4%[39]. - Total cash inflow from operating activities amounted to CNY 2,363,991,325.60, compared to CNY 2,078,714,633.90 in the previous year, indicating an increase of about 13.7%[39]. - Cash outflow from operating activities was CNY 1,950,392,580.25, up from CNY 1,684,955,726.04 in 2021, reflecting a rise of approximately 15.7%[39]. - The net cash flow from financing activities was CNY 1,510,419,345.07, contrasting with a negative flow of CNY -28,594,405.95 in the same period of 2021[40]. Shareholder Information - The company reported a total of 53,852 common shareholders at the end of the reporting period[20]. - The top ten shareholders collectively hold 99.99% of the company's shares, with the largest shareholder owning 36.73%[20]. Expenses and Investments - Research and development expenses rose to ¥171,277,340.73, up 42.3% from ¥120,389,823.11 in the previous year[34]. - The company received CNY 100,000,000.00 from other investment-related cash activities, down from CNY 415,000,000.00 in the previous year[39]. - The company paid CNY 407,896,428.45 to employees, which is an increase from CNY 353,444,711.06 in the previous year, reflecting a rise of about 15.4%[39].